Senti Biosciences Holdings (SNTI) Accumulated Expenses (2021 - 2025)

Senti Biosciences Holdings' Accumulated Expenses history runs 5 years deep, the most recent figure standing at $5.4 million for Q4 2025.

• In Q4 2025, Accumulated Expenses fell 16.15% year-over-year to $5.4 million; the TTM figure through Dec 2025 stood at $5.4 million (down 16.15% YoY), while the FY2025 annual figure was $5.4 million, down 16.15% from the prior year.
• Accumulated Expenses for Q4 2025 stood at $5.4 million, up from $5.1 million in the prior quarter.
• The five-year high for Accumulated Expenses was $12.6 million in Q4 2022, with the low at $1000.0 in Q1 2021.
• The 5-year median for Accumulated Expenses is $4.5 million (2023), against an average of $4.9 million.
• The sharpest annual moves came in 2022 and 2023: Accumulated Expenses soared 396732.4% in 2022, then sank 66.06% in 2023.
• Senti Biosciences Holdings' Accumulated Expenses stood at $5.3 million in 2021, then surged by 135.9% to $12.6 million in 2022, then slumped by 52.87% to $5.9 million in 2023, then rose by 7.73% to $6.4 million in 2024, then decreased by 16.15% to $5.4 million in 2025.
• Business Quant data shows SNTI's Accumulated Expenses at $5.4 million in Q4 2025, $5.1 million in Q3 2025, and $3.6 million in Q2 2025.